{"prompt": "['required for participation in the study, and to be consistent with this, no proactive collection', 'of pregnancy information for female partners of male patients treated with emicizumab will', 'be required.', '5.4.3.3', 'Abortions', 'Any abortion should be classified as a serious adverse event (as the Sponsor considers', 'abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to', 'the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see', 'Section 5.4.2).', '5.4.3.4', 'Congenital Anomalies/Birth Defects', 'Any congenital anomaly/birth defect in a child born to a female patient exposed to', 'emicizumab should be classified as a serious adverse event, recorded on the Adverse Event', 'eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of', 'the event; see Section 5.4.2).', '5.5', 'FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS', '5.5.1', 'Investigator Follow-Up', 'The investigator should follow each adverse event until the event has resolved to baseline', 'grade or better, the event is assessed as stable by the investigator, the patient is lost to', 'follow-up, or the patient withdraws consent. Every effort should be made to follow all serious', 'adverse events considered to be related to study drug or trial-related procedures until a final', 'outcome can be reported.', 'During the study period, resolution of adverse events (with dates) should be documented on', \"the Adverse Event eCRF and in the patient's medical record to facilitate source data\", 'verification.', 'All pregnancies reported during the study should be followed until pregnancy outcome. At', 'the time of pregnancy outcome, reporting instructions provided in Section 0 should be', 'followed.', '5.5.2', 'Sponsor Follow-Up', 'For serious adverse events, adverse events of special interest, and pregnancies, the', 'Sponsor or a designee may follow up by telephone, fax, electronic mail, and/or a monitoring', 'visit to obtain additional case details and outcome information (e.g., from hospital discharge', 'summaries, consultant reports, autopsy reports) in order to perform an independent medical', 'assessment of the reported case.', '5.6', 'ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE EVENT', 'REPORTING PERIOD', 'The Sponsor should be notified if the investigator becomes aware of any serious adverse', 'event that occurs after the end of the adverse event reporting period (defined as the end of', 'the 2-year treatment period), if the event is believed to be related to prior study drug', 'treatment. These events should be reported through use of the Adverse Event eCRF.', 'However, if the EDC system is not available, the investigator should report these events', 'Emicizumab - F. Hoffmann-La Roche Ltd', '141 / Protocol MO39129, Version 3']['directly to the Sponsor or its designee, either by faxing or by scanning and emailing the', 'Serious Adverse Event/Adverse Event of Special Interest Reporting Form using the fax', 'number or email address provided to investigators.', '5.7', 'EXPEDITED REPORTING TO HEALTH AUTHORITIES,', 'INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND', 'ETHICS COMMITTEES', 'The Sponsor will promptly evaluate all serious adverse events and adverse events of special', 'interest against cumulative product experience to identify and expeditiously communicate', 'possible new safety findings to investigators, IRBs, ECs, and applicable health authorities', 'based on applicable legislation.', 'To determine reporting requirements for single adverse event cases, the Sponsor will assess', 'the expectedness of these events using the following reference document:', \"Emicizumab Investigator's Brochure.\", 'The Sponsor will compare the severity of each event and the cumulative event frequency', 'reported for the study with the severity and frequency reported in the applicable reference', 'document.', \"Reporting requirements will also be based on the investigator's assessment of causality and\", 'seriousness, with allowance for upgrading by the Sponsor as needed.', '6.', 'STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN', 'The primary analysis population is all patients who have received at least one dose of', 'emicizumab (safety population). The intent-to-treat (ITT) population includes all enrolled', 'patients.', 'No formal statistical hypothesis tests will be performed and all analyses are considered', 'descriptive.', '6.1', 'DETERMINATION OF SAMPLE SIZE', 'A sample size of approximately 200 patients is planned for this study.', 'For the purpose of the sample size calculation, the incidence of adverse events was chosen', 'as the safety endpoint of primary interest.', 'If the observed incidence of adverse events is between 2.5% and 15%, the precision for the', 'estimated incidence rate is presented below according to the 95% Clopper-Pearson', 'confidence intervals (CIs) (Table 14).', 'Emicizumab - F. Hoffmann-La Roche Ltd', '142 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}